Ling Fang

Prof. Ling Fang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ZZZhiwei Zheng
Zhiwei Zheng
HZHuide Zhu
Huide Zhu
LFLing Fang
Ling Fang
HCHongfu Cai
Hongfu Cai
Objective: Sugemalimab is approved in China as a first-line treatment in combination with chemotherapy for metastatic nonsquamous non-small cell lung cancer (NSCLC). This study aims to evaluate the cost-effectiveness of first-line additional sugemalimab in combination with chemotherapy vs. chemotherapy from the perspective of the Chinese healthcare system.Materials and methods: A three-state Markov model was designed to evaluate the costs and quality-adjusted life years (QALYs) of first-line sugemalimab combination with chemotherapy vs. chemotherapy over a 10-year period. Data on clinical outcomes were obtained from GEMSTONE-302 clinical trials. Costs and health utilities were collected from local databases and published literature. The uncertainty of the model parameters was explored through sensitivity analysis.Results: Compared to chemotherapy, sugemalimab treatment for NSCLC resulted in an extra 0.50 QALYs at an additional cost of $73627.99, with an incremental cost-effectiveness ratio (ICER) of 148354.07/QALY at the willingness-to-pay (WTP) threshold of $37663.26/QALY. One-way sensitivity analysis indicated that the primary motivator in this model was the cost of sugemalimab. However, none of the parameters significantly affected the model’s results.Conclusion: Sugemalimab combination therapy is not economically advantageous for the first-line management of metastatic non-squamous NSCLC, according to the Chinese healthcare system.

7 September 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYuling Zhang
Yuling Zhang
XHXiaoting Huang
Xiaoting Huang
SFShanna Feng
Shanna Feng
CCChen Chen
Chen Chen
DGDainian Guo
Dainian Guo
LFLing Fang
Ling Fang
Platinum-based chemotherapy drugs cause platinum accumulation and result in cancer-related fatigue (CRF), which is related to immune response through still ambiguous mechanisms. We aimed to explore the correlation between platinum and CRF from the perspective of platinum accumulation. After allowing for complete metabolism of the administered platinum drugs, we collected blood samples from 135 patients who had at least two platinum chemotherapy rounds, correlated the platinum concentration (C-Pt), pro-inflammatory cytokines IL-8 and TNF-α, hematological index with therapeutic effect, adverse reactions and fatigue. The median platinum concentration was higher in patients treated with cisplatin than oxaliplatin (424.0 vs 211.3 μg/L), and the occurrence of fatigue was 64.4% in all subjects. Separately, the incidence and degree of fatigue were 74.1% and 9.5 in the patients with higher platinum concentration compared to 57.1% and 2.0 in the lower group. C-Pt, IL-8 and TNF-α were positively correlated with the degree of CRF, while erythrocyte count and hemoglobin were negatively correlated with the degree of CRF. Mediating effect analysis showed that increased IL-8 concentration mediated 57.4%, while decreased erythrocyte count mediated 24.1% of the C-Pt effect on CRF. Platinum accumulation may involve increasing IL-8, cause inflammation or aggravate anemia, which in combination lead to CRF.

12 August 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YZYuling Zhang
Yuling Zhang
JZJieting Zheng
Jieting Zheng
YJYi Jiang
Yi Jiang
XHXuchun Huang
Xuchun Huang
LFLing Fang
Ling Fang
Previous studies only focused on different adverse reactions caused by various platinum drugs, but not on common immunotoxicity caused by the accumulation of elemental platinum. Here, we determined the serum platinum concentrations of cancer patients after a metabolism period of platinum drug chemotherapy, in addition to hematological indices and subsequent immune-related adverse reactions, then analyzed the correlations between platinum accumulation, immune cell levels, and immune-toxicity. We chose the day before the next round of chemotherapy as the specified time point for blood sampling. Samples were collected at five time points, separately in oxaliplatin and cisplatin groups. The median serum platinum concentrations in all patients was 294.8 (205.6, 440.3) μg/L, and was approximately two-fold greater in the cisplatin group than in the oxaliplatin group (429.3 vs. 211.7 μg/L). The platinum level of both groups peaked at the third time point, with the average of females being higher than males (383.9 vs. 266.5 μg/L), and was positively correlated with leukocyte and platelet counts, but negatively correlated with erythrocyte counts and concentration of hemoglobin. The risks of anemia and adverse reactions were individually increased by 0.002- and 0.007-fold for every μg/L increase of platinum concentration. To our knowledge, this is the first study on the relationship between platinum accumulation, immune cell levels and toxicity, showing that drug-induced platinum accumulation may interfere with immune cells and thus increase the risk of toxicity.

20 September 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
WLWenXin Lin
WenXin Lin
JCJiaoling Chen
Jiaoling Chen
NLNan Li
Nan Li
XCXiaorui Cai
Xiaorui Cai
LFLing Fang
Ling Fang
CCCong Chen
Cong Chen
Background: Ferroptosis is a recently identified form of regulated cell death that is closely associated with oxidative stress and redox homeostasis. Although ferroptosis-related prognostic models have been developed for hepatocellular carcinoma (HCC), the prognostic value of integrating oxidative stress-related features with ferroptosis-associated alterations remains unclear. Methods: We identified oxidative stress- and ferroptosis-related genes (OFRGs) and developed a prognostic signature for HCC using transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) cohorts. Consensus clustering based on OFRG expression profiles revealed distinct molecular subgroups with different survival outcomes. Kaplan-Meier and ROC analyses assessed the prognostic performance. GO, KEGG, Tumor Mutation Burden and Immune Checkpoints and Tumor Microenvironment analyses uncovered underlying molecular pathways. Functional experiments including CCK-8, Clone Formation Tests, Wound Healing Assay and Western Blotting further validated these mechanisms. Results: A three-gene prognostic model consisting of AKR1B15, S100A9, and ADH4 was established using Cox regression and LASSO analyses. The risk score effectively stratified HCC patients according to overall survival in internal validation cohorts, while external validation demonstrated moderate predictive performance, particularly for short- and intermediate-term survival prediction. The risk score was also associated with differences in immune infiltration patterns, immune checkpoint expression, and predicted drug sensitivity. Among the signature genes, ADH4, previously reported to be associated with HCC prognosis, was downregulated in HCC tissues and independently correlated with patient survival. Functional assays showed that ADH4 overexpression inhibited HCC cell proliferation and migration in vitro. Conclusions: Collectively, this study provides an oxidative stress- and ferroptosis-associated prognostic framework for HCC and identifies ADH4 as a candidate biomarker with preliminary functional evidence, requiring further mechanistic validation.